The Current Landscape of Early Drug Development for Patients With Sarcoma

Breelyn A. Wilky, Robin L. Jones, Vicki L. Keedy

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations


Until recently, advancements in the treatment of patients with adult soft tissue sarcomas have been relatively slow. This is, in part, due to their heterogeneity and rarity. A better understanding of the biology and differences among the various histologies has led to substantial growth in novel strategies. In addition to novel cytotoxic chemotherapies, agents targeting platelet-derived growth factor receptor-α (PDGFRα), mTOR, and angiogenesis are areas of active investigation. Additionally, with the success of checkpoint inhibitors in other malignancies and early encouraging results of checkpoint inhibitors in some sarcoma subtypes, this approach is being widely investigated in various sarcomas. As we increasingly recognize and treat each sarcoma histology as a separate disease, it is important to spread awareness of the exciting clinical trials available to our patients with these rare malignancies.

Original languageEnglish (US)
Pages (from-to)807-810
Number of pages4
JournalAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting
StatePublished - 2017
Externally publishedYes

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'The Current Landscape of Early Drug Development for Patients With Sarcoma'. Together they form a unique fingerprint.

Cite this